Patents Assigned to CHASE THERAPEUTICS CORPORATION
  • COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20200016127
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.
    Type: Application
    Filed: March 26, 2018
    Publication date: January 16, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH